Clinical trials with MTDQ /6,6'-methylene-bis (2,2,4-trimethyl-1,2-dihydroquinoline)/ an antioxidant with radiation sensitizing effect.
Daily doses of 1320 mg MTDQ have been administered orally to 7 patients for 100 subsequent days. Biological half-life and serum concentration measurements were performed. Function of vital organs, as well as routine laboratory findings revealed that MTDQ did not induce any toxic changes. The effect of MTDQ on the radiosensitivity of hypoxic tumor cells was studied in a combined treatment modality including 12 patients. The action on tumor regression was found encouraging. It has been found remarkable, too, that due to the effect of MTDQ and radiotherapy some of the nonspecific and general symptoms (e. g. pruritus) also disappeared.
D002986:Clinical Trials as Topic; D006207:Half-Life; D006801:Humans; D011804:Quinolines / Q000097:blood / Q000494:pharmacology*; D011838:Radiation-Sensitizing Agents / Q000097:blood / Q000494:pharmacology*
D011804:Quinolines; D011838:Radiation-Sensitizing Agents